"Proto-Oncogene Proteins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Products of proto-oncogenes. Normally they do not have oncogenic or transforming properties, but are involved in the regulation or differentiation of cell growth. They often have protein kinase activity.
| Descriptor ID |
D011518
|
| MeSH Number(s) |
D12.776.624.664.700
|
| Concept/Terms |
Proto-Oncogene Proteins- Proto-Oncogene Proteins
- Proto Oncogene Proteins
- Proto-Oncogene Products, Cellular
- Cellular Proto-Oncogene Products
- Proto Oncogene Products, Cellular
- Proto Oncogene Proteins, Cellular
- c-onc Proteins
- c onc Proteins
- Cellular Proto-Oncogene Proteins
- Cellular Proto Oncogene Proteins
- Proto-Oncogene Proteins, Cellular
|
Below are MeSH descriptors whose meaning is more general than "Proto-Oncogene Proteins".
Below are MeSH descriptors whose meaning is more specific than "Proto-Oncogene Proteins".
This graph shows the total number of publications written about "Proto-Oncogene Proteins" by people in this website by year, and whether "Proto-Oncogene Proteins" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 9 | 3 | 12 |
| 1997 | 10 | 9 | 19 |
| 1998 | 4 | 1 | 5 |
| 1999 | 7 | 5 | 12 |
| 2000 | 8 | 8 | 16 |
| 2001 | 7 | 10 | 17 |
| 2002 | 20 | 22 | 42 |
| 2003 | 14 | 19 | 33 |
| 2004 | 23 | 12 | 35 |
| 2005 | 6 | 6 | 12 |
| 2006 | 3 | 6 | 9 |
| 2007 | 7 | 3 | 10 |
| 2008 | 7 | 6 | 13 |
| 2009 | 9 | 2 | 11 |
| 2010 | 11 | 13 | 24 |
| 2011 | 10 | 6 | 16 |
| 2012 | 13 | 10 | 23 |
| 2013 | 13 | 8 | 21 |
| 2014 | 16 | 6 | 22 |
| 2015 | 18 | 2 | 20 |
| 2016 | 5 | 6 | 11 |
| 2017 | 4 | 4 | 8 |
| 2018 | 7 | 7 | 14 |
| 2019 | 8 | 2 | 10 |
| 2020 | 5 | 2 | 7 |
| 2021 | 4 | 6 | 10 |
| 2022 | 4 | 4 | 8 |
| 2023 | 2 | 5 | 7 |
| 2024 | 6 | 1 | 7 |
| 2025 | 5 | 3 | 8 |
| 2026 | 2 | 1 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Proto-Oncogene Proteins" by people in Profiles.
-
Targeting Menin in T-lineage Acute Lymphoblastic Leukemia. Mol Cancer Ther. 2026 Aug 04; 25(8):1294-1304.
-
Genomic Subtype Influences BH3 Mimetic Drug Sensitivity and Synergy with Cytotoxic Chemotherapeutics in T-cell Acute Lymphoblastic Leukemia. Clin Cancer Res. 2026 Jul 17; 32(14):3018-3030.
-
Menin-dependent megakaryocyte proliferation and fibrosis in myeloproliferative neoplasms. Cancer Cell. 2026 Aug 10; 44(8):1639-1652.e6.
-
Low-input proteomics identifies vWF as a negative regulator of Tet2 mutant hematopoietic stem cell expansion. Cell Rep. 2026 Jan 27; 45(1):116770.
-
Recurrent somatic copy number alterations in resected cerebral cavernous malformations. Hum Genomics. 2025 12 09; 20(1):12.
-
Chronic myelomonocytic leukemia in the young (aged 50 years and younger): Divergent clinical and molecular characteristics from the elderly. Cancer. 2025 Nov 15; 131(22):e70176.
-
A myeloid Tet2-IL-1ß axis modulates intestinal inflammation by restricting catecholaminergic stimulation of enterochromaffin cell differentiation. Immunity. 2025 Nov 11; 58(11):2785-2798.e4.
-
Apoptosis-targeting BH3 mimetics: transforming treatment for patients with acute myeloid leukaemia. Nat Rev Clin Oncol. 2025 Nov; 22(11):847-868.
-
Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study. Blood. 2025 Aug 28; 146(9):1065-1077.
-
Tet Methylcytosine Dioxygenase 2 (TET2) Mutation Drives a Global Hypermethylation Signature in Patients With Pulmonary Arterial Hypertension (PAH): Correlation With Altered Gene Expression Relevant to a Common T Cell Phenotype. Compr Physiol. 2025 04; 15(2):e70011.